Spike three products into the "clinical pathway treatment drug interpretation"


Release time:

2012-12-03

Recently, three products of cefmenoxime hydrochloride for injection (0.25g, 0.5g), amlodipine aspartate tablets and aceclofenac sustained-release tablets produced by Jianfeng Pharmaceutical Co., Ltd. have been incorporated into the relevant fascicles of "Interpretation of Clinical Pathway Therapeutic Drugs", which is very beneficial to the clinical promotion and sales of the three products.
In accordance with the spirit of the General Office of the State Council, the Ministry of Health started the pilot work of clinical pathway management in 2009, and the Press of Union Medical University of the Chinese Academy of Medical Sciences undertook the organization and compilation of "Clinical Pathway" and "Clinical Pathway Interpretation". Clinical pathways for 331 diseases in 22 disciplines including internal medicine, digestive system, neurology, and cardiovascular system. The Interpretation of Therapeutic Drugs in Clinical Pathway, compiled by the Expert Group on the Interpretation of Therapeutic Drugs in Clinical Pathway, elaborates in detail the drug-related information involved in the clinical pathway and the "choice of treatment plan" and "choice of medication plan" in the interpretation of the clinical pathway. Its purpose is to help the medical staff and managers of the trial clinical pathway medical unit to accurately understand, grasp and correctly use the clinical pathway, standardize medical behavior and improve medical quality, ensure medication safety. Therefore, "Clinical Pathway Treatment Drug Interpretation" is not only a reference for clinical pathway standardization, but also the best platform to help clinical staff and managers understand drug knowledge. The three products of Jianfeng Pharmaceutical have been reviewed and demonstrated by relevant experts, and have been successfully included in the relevant fascicle of "Interpretation of Clinical Pathway Therapeutic Drugs" by marking the trade name. Among them, Fanfweite (0.25g Cefmenoxime Hydrochloride for Injection) and Lixiaojun (0.5g Cefmenoxime Hydrochloride for Injection) are included in the drug forms of 22 disciplines in "Interpretation of Clinical Pathway Therapeutic Drugs", while Lester (L-Aspartate Amlodipine Tablets) is included in the drug forms of cardiovascular system, endocrinology and nephrology, yue Yining (Aceclofenac Sustained Release Tablets) is included in the drug form of five disciplines of orthopedics, oncology, general surgery, gynecology and renal internal medicine. It is reported that the "Interpretation of Clinical Pathway Treatment Drugs" has published five fascicles of cardiovascular system, neurosurgery, cardio-vascular surgery, hematology, and orthopedics, and has been distributed to more than 1400 clinical pathway management pilot hospitals in relevant provinces. The other fascicles will be published one after another. On the basis of the preliminary clinical pathway management pilot work, the provincial health administrative departments will further expand the number of clinical pathway management pilot hospitals within their jurisdiction, with the goal of reaching 50% of Grade 3A general hospitals and 20% of Grade A general hospitals by the end of 2012 to carry out clinical pathway management, and will be fully promoted and implemented in all medical institutions nationwide by the end of 2015.